Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Wall St futures mixed as Apple falls on margin warning, midterm results awaited
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.45), $0.14 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $87.87 million versus the consensus estimate of $86.89 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sportradar Group AG (SRAD) Reports In-Line Q3 EPS ; Offers Guidance
- Versant Corp. (VSNT) Reports Q3 EPS of $0.34 ; Offers Guidance
- The Marzetti Company (MZTI) Misses Q3 EPS by 23c
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
